Advertisement

Psoriasis Vulgaris and Arthopathica

  • Jörg Christoph Prinz

Keywords

Human Leukocyte Antigen Psoriatic Arthritis Single Nucleotide Polymorphism Psoriasis Patient Keratinocyte Proliferation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbas AK, Murphy KM, and Sher A (1996) Functional diversity of helper T lymphocytes. Nature, 383: 787–793CrossRefPubMedGoogle Scholar
  2. Adam O (1995) Anti-inflammatory diet in rheumatic diseases. Eur J Clin Nutr, 49: 703–717PubMedGoogle Scholar
  3. Arias A, Giles B, Eiermann T, Sterry W, and Pandey J (1997) Tumor necrosis factor-alpha gene polymorphism in psoriasis. Exp Clin Immunogenet, 14: 118–122PubMedGoogle Scholar
  4. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, and Docke WD (1998) IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest, 101: 783–794PubMedGoogle Scholar
  5. Asadullah K, Eskdale J, Wiese A, Gallagher G, Friedrich M, and Sterry W (2001) Interleukin-10 promoter polymorphism in psoriasis. J Invest Dermatol, 116: 975–978CrossRefPubMedGoogle Scholar
  6. Asumalahti K, Veal C, Laitinen T, Suomela S, Allen M, Elomaa O, Moser M, de Cid R, Ripatti S, Vorechovsky I, Marcusson J, Nakagawa H, Lazaro C, Estivill X, Capon F, Novelli G, Saarialho Kere U, Barker J, Trembath R, and Kere J (2002) Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet, 11: 589–597CrossRefPubMedGoogle Scholar
  7. Baker BS, Powles AV, Malkani AK, Lewis H, Valdimarsson H, and Fry L (1991) Altered cell-mediated immunity to group A haemolytic streptococcal antigens in chronic plaque psoriasis. Br J Dermatol, 125: 38–42PubMedGoogle Scholar
  8. Baker BS, Bolith S, Powles AV, Valdimarsson H, and Fry L (1992) Streptococcal antigen-specific T lymphocytes in skin lesions of guttate psoriasis. J Invest Dermatol, 98: 535–538Google Scholar
  9. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, and Cooper KD (1995) Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest, 95: 317–327PubMedGoogle Scholar
  10. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, and Cormane RH (1983) Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res, 275: 181–189CrossRefPubMedGoogle Scholar
  11. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, and Kapsenberg ML (1989) Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res, 281: 24–30CrossRefPubMedGoogle Scholar
  12. Bowcock A, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez Vina M, and Menter A (2001) Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet, 10: 1793–1805CrossRefPubMedGoogle Scholar
  13. Brandrup F, Holm N, Grunnet N, Henningsen K, and Hansen HE (1982) Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol, 62: 229–236PubMedGoogle Scholar
  14. Braun-Falco O and Christophers E (1974) Structural aspects of initial psoriatic lesions. Arch Dermatol Forsch, 251: 95–110PubMedGoogle Scholar
  15. Chang JCC, Smith LR, Froning KJ, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DI, Carlo DJ, and Brostoff SW (1994) CD8+T cells in psoriatic lesions preferentially use T-cell receptor V?3 and/orV?13.1 genes. Proc Natl Acad Sci USA, 91: 9282–9286PubMedGoogle Scholar
  16. Chang JC, Smith LR, Froning KJ, Kurland HH, Schwabe BJ, Blumeyer KK, Karasek MA, Wilkinson DI, Farber EM, Carlo DJ, and Brostoff SW (1997) Persistence of T-cell clones in psoriatic lesions. Arch Dermatol, 133: 703–708CrossRefPubMedGoogle Scholar
  17. Christophers E and Henseler T (1985) Characterization of disease patterns in nonpustular psoriasis. Semin Dermatol, 4: 271–275Google Scholar
  18. Cookson W, Ubhi B, Lawrence R, Abecasis G, Walley A, Cox H, Coleman R, Leaves N, Trembath R, Moffatt M, and Harper J (2001) Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet, 27: 372–373CrossRefPubMedGoogle Scholar
  19. Dirckx JH (1983) Dermatologic terms in the De Medicina of Celsus. Am J Dermatopathol, 5: 363–369Google Scholar
  20. Edlund E, Johnsson U, Lidgren L, Pettersson H, Sturfelt G, Svensson B, Theander J, and Willen H (1988) Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis, 47: 809–815PubMedGoogle Scholar
  21. Elder J, Nair R, Henseler T, Jenisch S, Stuart P, Chia N, Christophers E, and Voorhees J (2001) The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol, 137: 1447–1454PubMedGoogle Scholar
  22. Farber EM, Nall ML, and Watson W (1974) Natural history of psoriasis in 61 twin pairs. Arch Dermatol, 109: 207–211PubMedGoogle Scholar
  23. Farber EM (1992) History of the treatment of psoriasis. J Am Acad Dermatol, 27: 640–645PubMedGoogle Scholar
  24. Fujinami RS and Oldstone MB (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science, 230: 1043–1045PubMedGoogle Scholar
  25. Glickman FS (1986) Lepra, psora, psoriasis. J Am Acad Dermatol, 14: 863–866PubMedGoogle Scholar
  26. Gonzalez S, Martinez Borra J, Torre Alonso J, Gonzalez Roces S, Sanchez del Rio J, Rodriguez Perez A, Brautbar C, and Lopez Larrea C (1999) The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum, 42: 1010–1016CrossRefPubMedGoogle Scholar
  27. Gordon M and Johnson WC (1967) Histopathology and histochemistry of psoriasis. I. The active lesion and clinically normal skin. Arch Dermatol, 95: 402–407CrossRefPubMedGoogle Scholar
  28. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, and Krueger JG (1995) Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med, 1: 442–447CrossRefPubMedGoogle Scholar
  29. Gudjonsson J, Karason A, Antonsdottir A, Runarsdottir E, Hauksson V, Upmanyu R, Gulcher J, Stefansson K, and Valdimarsson H (2003) Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol, 148: 233–235PubMedGoogle Scholar
  30. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, and Jonsdottir I (1999) Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol, 117: 580–586CrossRefPubMedGoogle Scholar
  31. Halpern SM, Anstey AV, Dawe RS, Diffey BL, Farr PM, Ferguson J, Hawk JL, Ibbotson S, McGregor JM, Murphy GM, Thomas SE, and Rhodes LE (2000) Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol, 142: 22–31CrossRefPubMedGoogle Scholar
  32. Harder J, Bartels J, Christophers E, and Schroder JM (1997) A peptide antibiotic from human skin. Nature, 387: 861CrossRefPubMedGoogle Scholar
  33. Harvima IT, Naukkarinen A, Harvima RJ, and Horsmanheimo M (1989) Enzyme-and immunohistochemical localization of mast cell tryptase in psoriatic skin. Arch Dermatol Res, 281: 387–391CrossRefPubMedGoogle Scholar
  34. Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JAW, Robarge J, Ott J, Kwok P-Y, Menter A, and Bowcock AM (2003) A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet, 35: 349–356CrossRefPubMedGoogle Scholar
  35. Henseler T (1997) The genetics of psoriasis. J Am Acad Dermatol, 37: S1–11Google Scholar
  36. Henseler T (1998) Genetics of psoriasis. Arch Dermatol Res, 290: 463–476CrossRefPubMedGoogle Scholar
  37. Homey B, Alenius H, Muller A, Soto H, Bowman E, Yuan W, McEvoy L, Lauerma A, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, and Zlotnik A (2002) CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med, 8: 157–165CrossRefPubMedGoogle Scholar
  38. Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, Nakajima N, Okada M, and Saito T (2002) Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J Immunol, 168: 541–544PubMedGoogle Scholar
  39. Jenisch S, Koch S, Henseler T, Nair RP, Elder JT, Watts CE, Westphal E, Voorhees JJ, Christophers E, and Kronke M (1999) Corneodesmosin gene polymorphism demonstrates strong linkage disequilibrium with HLA and association with psoriasis vulgaris. Tissue Antigens, 54: 439–449CrossRefPubMedGoogle Scholar
  40. Kagi MK, Wüthrich B, Montano E, Baradun J, Blaser K, and Walker C (1994) Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol, 103: 332–340PubMedGoogle Scholar
  41. Koo J and Lebwohl M (1999) Duration of remission of psoriasis therapies. J Am Acad Dermatol, 41: 51–59PubMedGoogle Scholar
  42. Leach D and Beckwith J (1999) The founders of dermatology: Robert Willan and Thomas Bateman. J R Coll Physicians Lond, 33: 580–582PubMedGoogle Scholar
  43. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, and Weinstein G (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis [see comments]. J Am Acad Dermatol, 39: 464–475PubMedGoogle Scholar
  44. Mallon E, Bunce M, Savoie H, Rowe A, Newson R, Gotch F, and Bunker C (2000) HLA-C and guttate psoriasis. Br J Dermatol, 143: 1177–1182PubMedGoogle Scholar
  45. McCarty, M. 1973, Host-parasite relations in bacterial diseases: Davis, B. D., Dulbecco, R., Eisen, H. N., Ginsberg, H. S., Wood, W. B., and McCarty, M. v. 2nd, (22):p. 627–665. Microbiology. Harper & Row: Hagerstown, New York, Evanstown, San Francisco, LondonGoogle Scholar
  46. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gürtler L, Riethmüller G, and Prinz JC (1995) Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol, 155: 4078–4083PubMedGoogle Scholar
  47. Michel G, Kemény L, Homey B, and Ruzicka T (1996) FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today, 17: 106–108CrossRefPubMedGoogle Scholar
  48. Moll JM and Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum, 3: 55–78CrossRefPubMedGoogle Scholar
  49. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Piepkorn M, Stern RS, Weinstein GD, and Whitmore SE (1998) Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol, 134: 595–598CrossRefPubMedGoogle Scholar
  50. Mrowietz U, Christophers E, and Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol, 141: 424–429CrossRefPubMedGoogle Scholar
  51. Mueller W and Hermann B (1976) Cyclosporin A for psoriasis. N Engl J Med, 301: 355Google Scholar
  52. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk W, Westphal E, Guo SW, Christophers E, Voorhees JJ, and Elder JT (1997) Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet, 6: 1349–1356CrossRefPubMedGoogle Scholar
  53. Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees JJ, and Elder JT (2000) Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet, 66: 1833–1844CrossRefPubMedGoogle Scholar
  54. Nickoloff BJ, Karabin GD, and Barker JNWN (1991) Localization of IL-8 and its inducer TNF-? in psoriasis. Am J Pathol, 138: 129–140PubMedGoogle Scholar
  55. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, and Revillard P (1991) CD4 antibody treatment of severe psoriasis. Lancet, 338: 321CrossRefGoogle Scholar
  56. Norrlind R (1954) Significance of infections in origination of psoriasis. Acta Rheum Scand, 1: 135–140Google Scholar
  57. Oldstone MB (1987) Molecular mimicry and autoimmune disease. Cell, 50: 819–820CrossRefPubMedGoogle Scholar
  58. Pinkus H and Mehregan AH (1966) The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol, 46: 109–116PubMedGoogle Scholar
  59. Prinz JC, Braun-Falco O, Meurer M, Daddona P, Reiter C, Rieber EP, and Riethmüller G (1991) Chimeric CD4 monoclonal antibody in the treatment of generalized pustular psoriasis. Lancet, 338: 320–321Google Scholar
  60. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, and Plewig G (1994) T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro. Eur J Immunol, 24: 593–598PubMedGoogle Scholar
  61. Prinz JC, Vollmer S, Boehncke W-H, Menssen A, Laisney I, and Trommler P (1999) Selection of conserved TCR-VDJ-rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol, 29: 3360–3368CrossRefPubMedGoogle Scholar
  62. Prinz JC (2003) The role of T cells in psoriasis. J Eur Ac Derm Venerol, 17: 257–270CrossRefGoogle Scholar
  63. Prinz JC (2004) Disease mimicry: A pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry? Autoimmun Rev, 3: 10–15PubMedGoogle Scholar
  64. Prodeus AP, Zhou X, Maurer M, Galli SJ, and Carroll MC (1997) Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature, 390: 172–175CrossRefPubMedGoogle Scholar
  65. Prokunina L, Castillejo Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes A, Tentler D, Kristjansdottir H, Grondal G, Bolstad A, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer Varela J, Jonsson R, Gyllensten U, Harley J, Alarcon Segovia D, Steinsson K, and Alarcon Riquelme M (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet, 32: 666–669CrossRefPubMedGoogle Scholar
  66. Queiro R, Torre J, Gonzalez S, Lopez Larrea C, Tinture T, and Lopez Lagunas I (2003) HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. J Rheumatol, 30: 505–507PubMedGoogle Scholar
  67. Ragaz A and Ackerman AB (1979) Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings. Am J Dermato-pathol, 1: 199–214Google Scholar
  68. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., and Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol, 41: 401–407PubMedGoogle Scholar
  69. Reczek D, Berryman M, and Bretscher A (1997) Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J Cell Biol, 139: 169–179CrossRefPubMedGoogle Scholar
  70. Reich K, Mossner R, Konig I, Westphal G, Ziegler A, and Neumann C (2002) Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-lbeta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol, 118: 155–163CrossRefPubMedGoogle Scholar
  71. Robinson JH and Kehoe MA (1992) Group A streptococcal M proteins: virulence factors and protective antigens. Immunol Today, 13: 362–367PubMedGoogle Scholar
  72. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, and Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol, 38: 478–485PubMedGoogle Scholar
  73. Russel TJ, Schultes LM, and Kuban DJ (1972) Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med, 287: 738–740PubMedGoogle Scholar
  74. Schaible UE, Collins HL, and Kaufmann SH (1999) Confrontation between intracellular bacteria and the immune system. Adv Immunol, 71: 267–377PubMedGoogle Scholar
  75. Schmitt Egenolf M, Eiermann TH, Boehncke WH, Stander M, and Sterry W (1996) Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1 *0701-DQA1 *0201-DQB1 *0303: a population and family-based study. J Invest Dermatol, 106: 711–714CrossRefPubMedGoogle Scholar
  76. Schroder JM and Harder J (1999) Human beta-defensin-2. Int J Biochem Cell Biol, 31: 645–651CrossRefPubMedGoogle Scholar
  77. Shelley WB and Kirschbaum JO (1961) Generalized pustular psoriasis. Arch Dermatol, 84: 73–78PubMedGoogle Scholar
  78. Sigmundsdottir H, Sigurgeirsson B, Troye Blomberg M, Good MF, Valdimarsson H, and Jonsdottir I (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol, 45:688–697CrossRefPubMedGoogle Scholar
  79. Tazi Ahnini R, Camp NJ, Cork MJ, Mee JB, Keohane SG, Duff GW, and di Giovine FS (1999) Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet, 8: 1135–1140CrossRefPubMedGoogle Scholar
  80. Tervaert WC and Esseveld H (1970) A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica, 140: 282–290PubMedGoogle Scholar
  81. Tokuhiro A, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, and Yamamoto K (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet, 35: 341–348CrossRefPubMedGoogle Scholar
  82. Tomfohrde J, Silverman A, Barnes R, Fernandez Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, and et al (1994) Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science, 264: 1141–1145PubMedGoogle Scholar
  83. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop GM, and Barker JN (1997) Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet, 6: 813–820CrossRefPubMedGoogle Scholar
  84. Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H, Asano N, Kishimoto M, Tanida Y, Kakinuma T, Mitsui H, Tada Y, Wakugawa M, Torii H, Komine M, Asahina A, and Tamaki K (2002) Interleukin-12 p40 gene (IL12B) 3′-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci, 30: 161–166CrossRefPubMedGoogle Scholar
  85. Valdimarsson H, Baker BS, Jonsdottir I, and Fry L (1986) Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today, 7: 256–259CrossRefGoogle Scholar
  86. Valdimarsson H, Sigmundsdottir H, and Jonsdottir I (1997) Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol, 107Suppl 1: 21–24CrossRefGoogle Scholar
  87. Vollmer S, Menssen A, Trommler P, Schendel D, and Prinz JC (1994) T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol, 24: 2377–2382PubMedGoogle Scholar
  88. Weinshenker BG, Bass BH, Ebers GC, and Rice GP (1989) Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol, 20: 1132–1133PubMedGoogle Scholar
  89. Weisenseel P, Laumbacher B, Besgen P, Ludolph-Hauser D, Herzinger T, Roecken M, Wank R, and Prinz JC (2002) Streptococcal infection distinguishes different types of psoriasis. J Med Genet, 39: 767–768CrossRefPubMedGoogle Scholar
  90. Zhou X, Krueger J, Kao M, Lee E, Du F, Menter A, Wong W, and Bowcock A (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics, 13: 69–78PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2005

Authors and Affiliations

  • Jörg Christoph Prinz

There are no affiliations available

Personalised recommendations